Novoic
Earlier Alzheimer's detection anywhere in 10 minutes
San Francisco Bay Area, United Kingdom · $2.6M raised
- Headquarters
- San Francisco Bay Area
- Employees
- 11–50
- Website
- novoic.com
- Total Funding
- $2.6M
- Last Round
- $2.6M SeedJul 2020
- Rounds
- 1
About
Novoic is a London-based clinical digital health company developing AI-powered speech biomarker software for the early detection of Alzheimer's disease and cognitive impairment. Its flagship product, Novoic Storyteller, uses brief automated speech recordings analyzed by proprietary algorithms to detect subtle cognitive changes and predict amyloid positivity — validated through the AMYPRED clinical trials. The platform serves 50+ medical institutions across the US in partnership with the Alzheimer's Disease Neuroimaging Initiative (ADNI), enabling scalable, remote screening for underserved communities.
Summary
Novoic is an Insurtech company based in San Francisco Bay Area, United Kingdom. It has raised $2.6M in total across 1 round, most recently a $2.6M Seed round in Jul 2020. Investors include Anthemis Exponential Ventures, APEX Capital and Entrepreneur First.
Tech & App Stack
2 technologies & apps tracked
Create a free account to track companies, build lists, and unlock premium data like the full tech & app stack.
Sign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Funding History
Jul 2020
Investors
Similar Companies

Health insurance company using technology to make health care simple, affordable, and accessible.
Coalition is a comprehensive insurance and cybersecurity platform that helps businesses manage an...
Digital health insurance company and healthcare super-app offering personalized health insurance,...

Chinese insurtech platform providing medical crowdfunding and an insurance marketplace connecting...

Ethos uses technology to provide accessible and affordable life insurance coverage.
Digital home insurance provider offering homeowners policies and proactive home maintenance tools...
